Moderna
MRNA
196.48
+9.02
+4.81%
Moderna
US · MRNA
#406 by market cap
Listed 2018
196.48
+9.02
+4.81%
Live - 5344 symbols - heartbeat 56s ago
· 2026-10-08 07:00
Pre-market
194.65
-0.93%
After-hours
195.47
-0.51%
Overnight
195.45
-0.52%
- Market cap
- 78.44B
- P/E (TTM)i
- -24.62
- P/Bi
- 11.60
- EPSi
- -7.26
- Div yieldi
- 0.00%
- 52W posi
- 92%
Reader sentiment
Are you bullish or bearish on MRNA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 13.36, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -39.93% YoY
Margins
- Gross margin
- 54.84%
- Operating margin
- -159.94%
- Net margin
- -146.83%
Key ratios & quality
- Enterprise valuei
- 73.27B
- Altman Z-Scorei
- 13.36
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 135.07M | 60.00M | 803.00M | 18.47B | 19.26B | 6.85B | 3.24B | 1.94B |
| Gross profit | 122.51M | 48.00M | 266.00M | 15.12B | 13.46B | 2.06B | 1.74B | 1.05B |
| Selling & admin expenses | 94.25M | 110.00M | 188.00M | 567.00M | 1.13B | 1.55B | 1.17B | 1.02B |
| Research & development | 454.08M | 496.00M | 1.37B | 1.99B | 3.30B | 4.85B | 4.54B | 3.13B |
| Operating profit | -413.27M | -546.00M | -763.00M | 13.30B | 9.42B | -4.24B | -3.95B | -3.07B |
| Pretax profit | -384.41M | -515.00M | -744.00M | 13.29B | 9.58B | -3.94B | -3.61B | -2.77B |
| Tax | 326.00K | -1.00M | 3.00M | 1.08B | 1.21B | 772.00M | -46.00M | 54.00M |
| Net profit | -384.73M | -514.00M | -747.00M | 12.20B | 8.36B | -4.71B | -3.56B | -2.82B |
| Basic EPS | -5 | -2 | -2 | 30 | 21 | -12 | -9 | -7 |
| Diluted EPS | -4.95 | -1.55 | -1.96 | 28.29 | 20.12 | -12.33 | -9.28 | -7.26 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 108.00M | 142.00M | 1.02B | 678.00M | 389.00M | 145.00M |
| Gross profit | 17.00M | 18.00M | 795.00M | 224.00M | -566.00M | 50.00M |
| Selling & admin expenses | 212.00M | 230.00M | 268.00M | 308.00M | 173.00M | 216.00M |
| Research & development | 856.00M | 700.00M | 801.00M | 775.00M | 649.00M | 651.00M |
| Operating profit | -1.05B | -907.00M | -260.00M | -857.00M | -1.39B | -815.00M |
| Pretax profit | -964.00M | -818.00M | -187.00M | -799.00M | -1.33B | -767.00M |
| Tax | 7.00M | 7.00M | 13.00M | 27.00M | 9.00M | 15.00M |
| Net profit | -971.00M | -825.00M | -200.00M | -826.00M | -1.34B | -782.00M |
| Basic EPS | -3 | -2 | -1 | -2 | -3 | -2 |
| Diluted EPS | -2.52 | -2.13 | -0.51 | -2.11 | -3.40 | -1.97 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.56B | 1.13B | 6.30B | 16.07B | 13.43B | 10.33B | 8.10B | 6.54B |
| Cash & ST investments | 1.52B | 1.10B | 4.61B | 10.73B | 9.90B | 8.60B | 7.03B | 5.80B |
| Inventory | -- | -- | 47.00M | 1.44B | 949.00M | 202.00M | 117.00M | 153.00M |
| Total assets | 1.96B | 1.59B | 7.34B | 24.67B | 25.86B | 18.43B | 14.14B | 12.34B |
| Total current liabilities | 222.80M | 143.12M | 4.39B | 9.13B | 4.92B | 3.02B | 2.21B | 1.99B |
| Short-term debt | -- | -- | 30.00M | 211.00M | 196.00M | 25.00M | 37.00M | 42.00M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | 590.00M |
| Total liabilities | 431,908,000.00 | 414,612,000.00 | 4,776,000,000.00 | 10,524,000,000.00 | 6,735,000,000.00 | 4,572,000,000.00 | 3,241,000,000.00 | 3,688,000,000.00 |
| Total equity | 1.53B | 1.17B | 2.56B | 14.15B | 19.12B | 13.85B | 10.90B | 8.65B |
| Retained earnings | -1.01B | -1.50B | -2.24B | 9.96B | 18.32B | 13.61B | 10.05B | 7.22B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 6.77B | 6.17B | 6.60B | 6.54B | 5.77B | 5.82B |
| Cash & ST investments | 5.98B | 5.13B | 4.50B | 5.80B | 5.21B | 5.14B |
| Inventory | 128.00M | 240.00M | 332.00M | 153.00M | 146.00M | 280.00M |
| Total assets | 12.70B | 12.01B | 12.14B | 12.34B | 11.49B | 10.96B |
| Total current liabilities | 1.60B | 1.57B | 1.68B | 1.99B | 2.40B | 2.53B |
| Short-term debt | 43.00M | 43.00M | 48.00M | 42.00M | 50.00M | 52.00M |
| Long-term debt | -- | -- | -- | 590.00M | 590.00M | 591.00M |
| Total liabilities | 2,638,000,000.00 | 2,611,000,000.00 | 2,805,000,000.00 | 3,688,000,000.00 | 4,080,000,000.00 | 4,200,000,000.00 |
| Total equity | 10.07B | 9.40B | 9.33B | 8.65B | 7.41B | 6.76B |
| Retained earnings | 9.07B | 8.25B | 8.05B | 7.22B | 5.88B | 5.10B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -330.87M | -459.00M | 2.03B | 13.62B | 4.98B | -3.12B | -3.00B | -1.87B |
| Depreciation & amortization | 24.86M | 31.00M | 31.00M | 232.00M | 348.00M | 621.00M | 189.00M | 215.00M |
| Free cash flow | -436.63M | -491.00M | 1.96B | 13.34B | 4.58B | -3.83B | -4.06B | -2.08B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 563.03M | 51.00M | 2.04B | -733.00M | -3.26B | 46.00M | 66.00M | 35.00M |
| Ending cash balance | 670.49M | 248.00M | 2.64B | 6.86B | 3.22B | 2.93B | 1.93B | 2.60B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -1.04B | -919.00M | -847.00M | 930.00M | -630.00M | -526.00M |
| Depreciation & amortization | 39.00M | 57.00M | 52.00M | 67.00M | 59.00M | 63.00M |
| Free cash flow | -1.16B | -922.00M | -880.00M | 891.00M | -692.00M | -563.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 3.00M | 14.00M | 2.00M | 16.00M | 19.00M | 23.00M |
| Ending cash balance | 1.63B | 1.28B | 1.13B | 2.60B | 1.91B | 1.72B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -82.11 | -38.00 | -39.99 | 146.08 | 50.27 | -28.59 | -28.77 | -28.87 |
| ROA %i | -26.38 | -28.95 | -16.74 | 76.25 | 33.10 | -21.29 | -21.87 | -21.31 |
| ROIC %i | -82.02 | -38.03 | -37.19 | 135.27 | 46.42 | -28.33 | -29.59 | -28.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | 7.25 | 17.95 | 19.80 | 22.02 |
| EBIT margin %i | -337.33 | -1,057.76 | -267.63 | 75.01 | 50.88 | -57.80 | -112.00 | -143.50 |
| FCF / sales %i | -- | -- | 713.88 | 75.19 | 24.27 | -- | -- | -- |
| Current ratioi | 7.02 | 7.89 | 1.43 | 1.76 | 2.73 | 3.42 | 3.67 | 3.29 |
| Quick ratioi | 6.97 | 7.82 | 1.37 | 1.54 | 2.35 | 3.21 | 3.45 | 3.06 |
| Debt / assetsi | 1.71 | 8.33 | 3.23 | 3.71 | 4.64 | 6.75 | 5.28 | 10.58 |
| LT debt / equityi | 2.19 | 11.27 | 8.08 | 4.98 | 5.25 | 8.79 | 6.51 | 14.60 |
| Interest coveragei | -- | -76.85 | -74.31 | 739.06 | 331.17 | -102.74 | -149.29 | -275.80 |
| Revenue CAGR (3Y) %i | -- | -22.10 | 15.69 | 425.08 | 632.63 | 191.03 | -43.50 | -53.30 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -29.34 | -27.50 | -29.32 | -28.87 | -36.56 | -39.00 |
| ROA %i | -22.81 | -20.97 | -22.31 | -21.31 | -26.41 | -27.43 |
| ROIC %i | -29.98 | -28.10 | -29.46 | -28.35 | -34.39 | -36.23 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -107.90 | -95.94 | -142.82 | -143.50 | -141.20 | -137.78 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.22 | 3.93 | 3.93 | 3.29 | 2.41 | 2.29 |
| Quick ratioi | 3.92 | 3.55 | 3.51 | 3.06 | 2.25 | 2.08 |
| Debt / assetsi | 5.86 | 6.17 | 6.05 | 10.58 | 11.30 | 11.74 |
| LT debt / equityi | 6.97 | 7.43 | 7.35 | 14.60 | 16.85 | 18.27 |
| Interest coveragei | -178.26 | -209.36 | -393.13 | -275.80 | -119.69 | -72.50 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- COVID is the largest reported line at 62.76% of revenue, across 3 reported segments.
- Other revenue follows at 35.17%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
COVID62.76%
Other revenue35.17%
Respiratory syncytial virus (RSV)2.07%
Quote time 2026-10-08 07:00:11 · For reference only, not investment advice and not tailored to your situation.